Business
TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead in 2026. As 2025 ends, the Company reflects on a transformative year marked by significant commercial progress, strategic partnerships, and...
About this update from Tempramed Technologies Ltd.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead in 2026.","length":384,"tagName":"p"},{"type":"text","content":"As 2025 ends, the Company reflects on a transformative year marked by significant commercial progress, strategic partnerships, and continued execution against its mission to address one of the world's most pressing healthcare challenges — ensuring the safety and efficacy of temperature-sensitive medications for millions of individuals using injectable medication globally.","length":383,"tagName":"p"},{"type":"text","content":""2025 represented an important year of execution and validation for TempraMed. As the Company moves into 2026, the focus remains on expanding access to its life-saving technology while continuing to innovate at the intersection of science, patient needs and global healthcare systems. I am proud of the team for the work they have done this year, and for years prior. We are transforming a major industry, and next year will be even more exciting than this one."— Ron Nagar, Chief Executive Officer of TempraMed.","length":523,"tagName":"p"},{"type":"text","content":"Ilan Cohen, Chairman of TempraMed commented, "I am extremely happy with the progress TempraMed made in 2025, from operational efficiencies to distribution and partnership expansion, as well as completing a public listing. We are addressing a long-standing global healthcare problem that directly impacts patient safety and outcomes. The Company's technology has the potential to redefine how temperature-sensitive medications are protected worldwide, creating meaningful value for patients, healthcare systems and shareholders alike. 2026 will be a strong year for the Company as we continue to expand and unlock commercialization opportunities globally. We look forward to providing continuous updates to our investors and stakeholders."","length":752,"tagName":"p"},{"type":"text","content":"2025 Highlights: Strategic Expansion and Preparing for Global Commercialization","length":79,"tagName":"p...